GlassScriptPhysician profile
Victoria E Smithers
NPI 1598714719
$9,460.89
in general payments reported to CMS, 2019-2025
53 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $401 · 2021: $870 · 2022: $1,336 · 2023: $1,495 · 2024: $1,717 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,653 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.11 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,101.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $918.87 | 2019-2022 | |
| Amgen INC. | $708.22 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $700.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $619.43 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $582.06 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $576.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $575.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $456.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $376.28 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $315.28 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $287.47 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $150.51 | 2021 | |
| Ironshore Pharmaceuticals INC. | $144.08 | 2019-2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.38 | 2022-2025 | Xifaxan |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Smithers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.